

## Supplementary table S2

Relationship between alteration in gene expression and survival data

### Univariate analysis for RFS and PFS

		RFS					PFS				
		n	Events	Median months	p	HR (95%CI)	n	Events	Median months	p	HR (95%CI)
<b>All Patients</b>		<b>25</b>	<b>14</b>	<b>27.30</b>			<b>32</b>	<b>21</b>	<b>21.87</b>		
<b>PTL</b>	RSCC*	7	3	40.03*	0.953	0.962 (0.267-3.464)	12	7	17.20	0.669	1.104 (0.701-1.740)
	LSCC <sup>§</sup>	18	11	21.43			20	14	19.47*		
<b>Age</b>	<65 years old	9	7	14.20	<b>0.072</b>	0.375 (0.129-1.091)	12	10	14.20	0.281	0.623 (0.262-1.483)
	≥65 years old * <sup>§</sup>	16	7	40.30			20	11	27.30		
<b>BGN</b>	No overexpression* <sup>§</sup>	8	3	NR	0.207	1,514 (0,795-2,882)	11	6	21,53	0.560	1,153 (0,714-1,862)
	Overexpression	17	11	16.93			21	15	21,87		
<b>OGN</b>	No underexpression	10	7	16.93	0.352	0,606 (0,211-1,739)	13	10	21,53	0,771	0,877 (0,363-2,119)
	Underexpression* <sup>§</sup>	15	7	40.03			19	11	21,87		
<b>CHAD</b> <i>n=17</i>	No underexpression	2	1	14.20	0.763	1,372 (0,175-10,757)	4	3	12,00	0.549	0,672 (0,183-2,464)
	Underexpression* <sup>§</sup>	15	8	21.43			16	11	21,53		
<b>PRELP</b> <i>n=17</i>	No underexpression* <sup>§</sup>	5	3	19.47	0.950	0,958 (0,254-3,619)	6	4	12,00	0.959	0,970 (0,303-3,106)
	Underexpression	12	8	21.43			14	10	21,43		
<b>PODN</b> <i>n=17</i>	No underexpression	6	5	12.23	<b>0.45</b>	<b>0.289 (0.086-0.975)</b>	7	6	12,00	0.246	0,533 (0,1840-1,545)
	Underexpression* <sup>§</sup>	11	6	27.30			13	8	21,53		

*n=25 patients after R0 resection (complete resection of primary ± metastasis) at diagnosis.*

*NR: not reached*

*\* indicates better RFS*

*§ indicates better PFS*